within Pharmacolibrary.Drugs.D_Dermatologicals.D01A_AntifungalsForTopicalUse.D01AE21_Flucytosine;

model Flucytosine
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_1C_enteral(
    weight = 70,
    F = 0.8,
    Cl = 2.9166666666666666e-06,
    adminDuration = 600,
    adminMass = 100 / 1000000,
    adminCount = 1,
    Vd = 0.0006,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.01155,
    Tlag = 10.200000000000001);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Flucytosine</td></tr><tr><td>ATC code:</td><td>D01AE21</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>1</td></tr>
    <tr><td>dosage:</td><td>100</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>0.6</td><td>L</td></tr>
    <tr><td>clearance:</td><td>2.5</td><td>mL/min/kg</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Flucytosine is an antifungal medication used primarily for the treatment of serious fungal infections, such as cryptococcal meningitis and systemic candidiasis, often in combination with other agents like amphotericin B. It is still in clinical use for these indications.</p><h4>Pharmacokinetics</h4><p>Typical pharmacokinetics in adult patients with normal renal function; reported parameters are from multiple clinical studies of oral administration.</p><h4>References</h4><ol><li><p>Kim, HY, et al., &amp; Alffenaar, JW (2020). Saliva for Precision Dosing of Antifungal Drugs: Saliva Population PK Model for Voriconazole Based on a Systematic Review. <i>Frontiers in pharmacology</i> 11 894–None. DOI:<a href=\"https://doi.org/10.3389/fphar.2020.00894\">10.3389/fphar.2020.00894</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/32595511/\">https://pubmed.ncbi.nlm.nih.gov/32595511</a></p></li><li><p>Dupont, B (2001). [Choice and use of antifungal drugs]. <i>La Revue du praticien</i> 51(7) 752–757. PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/11387672/\">https://pubmed.ncbi.nlm.nih.gov/11387672</a></p></li><li><p>Hayashi, Y, et al., &amp; Yamada, Y (1995). [Study of serial bronchoalveolar lavage in patients with aspergilloma: cell reaction at the affected sites and penetration of miconazole and flucytosine into the lesion]. <i>Kansenshogaku zasshi. The Journal of the Japanese Association for Infectious Diseases</i> 69(5) 517–523. DOI:<a href=\"https://doi.org/10.11150/kansenshogakuzasshi1970.69.517\">10.11150/kansenshogakuzasshi1970.69.517</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/7602184/\">https://pubmed.ncbi.nlm.nih.gov/7602184</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.D.D01AE21 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Flucytosine;
